GB2089208A - Antibacterial compositions containing 1-(2,3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole - Google Patents
Antibacterial compositions containing 1-(2,3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole Download PDFInfo
- Publication number
- GB2089208A GB2089208A GB8136309A GB8136309A GB2089208A GB 2089208 A GB2089208 A GB 2089208A GB 8136309 A GB8136309 A GB 8136309A GB 8136309 A GB8136309 A GB 8136309A GB 2089208 A GB2089208 A GB 2089208A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- oxyethyl
- form suitable
- nitroimidazole
- carboxypropionyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Pharmaceutical compositions for the treatment of diseases caused by anaerobic microorganisms comprise as the active ingredient 1-(2-3'- carboxypropionyl oxyethyl)-2-methyl-5- nitroimidazole or a pharmaceutically acceptable salt thereof. The compositions may be administered parenterally, orally, topically, rectally or vaginally.
Description
SPECIFICATION
Pharmaceutical composition containing 1-(2,3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole as active therapeutic agent against diseases caused by anaerobic germs
Background and Summary of the Invention
This invention relates to the derivatives of imidazole 1-(2-3'-carboxypropionyl oxyethyl)-2-methyl-5nitroimidazole having the formula:
and salts thereof with pharmaceutically acceptable inorganic or organic acids and bases, e.g., alkali metal, alkaline-earth metal, ammonia, aliphatic amino acid, i.e., mono- or di-ethanolamine and the cyclic amine salts and aliphatic amino acids.
More particularly, the invention relates to pharmaceutical compositions containing these derivatives and methods of treatment therewith of infections caused by anaerobic bacteria, e.g., Peptostreptococcus, Ba ctero ides fragilis, Bacteroides meianinogenicus, Furobacterium, Clostridium perfringens and other species of Clostridium.
The salts of Compound I have the added advantage of being soluble in water, which allows them to be caused for parenteral administration.
The use of 1-(2-3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole or salts may be used in combination with excipients or coatings normally used in pharmaceutical products.
Detailed Description of the Invention
In clinical practice, the compounds of the present invention are administered parenterally, rectally or topically.
The compositions for oral administration include tablets, sugar-coated pills, dispersable powders or granules. In these solid mixtures, the active compound is administered together with at least one inert diluent such as calcium carbonate, potato starch, alginic acid, microcrystalline cellulose, methyl cellulose, lactose or sucrose. The mixtures may also include additional substances other than the inert diluents, such as, for example, lubricating agents, e.g., magnesium stearate, stearic acid, talc. The liquid mixtures for oral administration include emulsions, solutions, suspensions, and pharmaceutically acceptable syrups and elixirs, also containing inert diluents. These mixtures may also contain additives such as humectant agents and sweetening, flavoring and aromatic suspensories and preservatives.The composions may also be compounded for oral administration in capsule form with an absorbable material such as gelatine, containing the active substance with or without the addition of diluents or excipients.
For parenteral administration, the compounds may be administered in aqueous or non-aqueous sterile solutions, suspensions or emulsions. Some examples of non-aqueous solvents or suspensory media are: propylene glycol, polyethylene glycol, dioxilanes, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. These mixtures may also contain additives such as preservative, humectant, emulsifying and dispersant agents. They may also be sterilized, for example, by filtration through bacteria-retaining filters, by incorporation into the mixture of sterilizing agents, by irradiation or by heating.
They may also be manufactured in the form of solid sterile mixtures which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
For topical application, the active substance may be incorporated into an appropriate vehicle such as a creme or unguent, or a pessary, ovule, or tablet for insertion into the vagina. The percentage of active ingredients in the mixtures of the present invention may vary in such a way that the proportion is appropriate for providing an adequate dosage with which to obtain the desired therapeutic effect.
It will be apparent that the composition may be administered at the same time in several different forms. In human therapy, the mixtures must generally be administered and the pharmaceutical compositions formulated in such a way that, in the case of oral or topical administration, 0.250 to 3.0 g of active substance is administered per day; in the case of parenteral administration, 0.150 to 1.5 g per day; and rectally, 0.125 to 2.0 per day.
Thus, the solutions described below in Examples I to Ill, VIII and IX may be administered intravenously to adult humans (500 mg every 8 hours) and 5 ml/min and to children under 12 (7.5 mg/kg-100 ml of solution) every eight hours at 5 ml/min.
The orally administrable dosages described below in Example IV to VI and X may be administered (500 mg) three times a day for seven days or more.
The rectally administrable composition of Example VII may be administered to adults 1-3 times a day for three days and after the fourth day a suppository every ten hours for four days. In children under 12 a dosage of 500 mg may be administered three times a day for three days and after the fourth day a suppository every twelve hours for four days.
The compounds and compositions may also be used as prophylactic agents in surgery as well as renal and hepatic abscesses and gangrene.
It will be understood that the foregoing dosage ranges are optimal and that variations therein are permissible within the spirit of the invention in certain instances.
The invention is illustrated by the following non-limiting examples;
Example I
In order to prepare an aqueous solution of 1-(2-3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole (I) at 35.0%, 35.0 g of the compound is dissolved in a mixture of diethanolamine (13.56 g) and water (50 cc) and is brought to a volume of 100 cc with water.
The pH of the solution obtained is approximately 6.
Example Il In order to prepare a 35.0% aqueous solution of the magnesium salt of (I), 35.0 g of (I) are made to react with basic magnesium carbonate (5.9 g) mixed with water (70 cc), stirring and heating to approximately 50"C.
When it has ceased giving off gas, it is brought to a volume of 100 cc with water and filtered. The solution obtained has a pH of approximately 5.7.
Example 111 In order to prepare a 25.0% aqueous solution of the sodium salt of (1), 35.0 g of (I) is made to react with sodium bicarbonate (10.76 g), mixing with water (40 cc), stirring and heating to approximately 50"C. When it has ceased giving off gas, it is brought to a volume of 100 ce with water and filtered.
The solution obtained has a pH of approximately 6.5.
Example IV
Tablets for oral administration, prepared by the usual technique, having the following composition:
1 -(2-3'-carboxypropionyl oxyethyl)- 2-methyl-5-nitroimidazole 0.250 g
Starch 0.190g
Aerosil 200 0.050 g
Magnesium stearate 0.025g Example V
Tablets for oral administration, prepared by the usual technique, have the following composition: 1-(2-3'-carboxypropionyl oxyethyl)
2-methyl-5-nitroimidazole 0.500 g
Plasdone 0.0259 Avicel pH 102 0.130 g
Talc 0.014g
Magnesium stearate 0.005g Colorant 0.014 9 Example VI
Vaginal tablets, prepared by the usual technique, have the following composition::
1 -(2-3'-ca rboxypropionyl oxyethyl)
2-methyl-5-nitroimidazole 0.500g Cornstarch 0.683g Alginic acid 0.050 g
Aerosil 200 0.060g Magnesium stearate 0.0010 g Example VII
Vaginal ovules or suppositories, prepared by the usual technique, have the following composition:
1 -(2-3'-carboxypropionyl oxyethyl )
2-methyl-5-nitroimidazole 20.83 g
Sodium hydroxide solution 0.1 N 72.00 cc
Manitol 30.00 g
Timerosal 0.00025g Distilled water s.q. 100.00 cc
The solution is sterilized by means of 0.22 sterile membrane filter and is placed in ampul bottles to be lyophilized from 5 cc into 3.0 cc portions. The product may be reconstituted for use with 3 cc of sterile water for injection.
Example IX
A solution for injection:
8 g of micronized powder of 1 -(2-3'-carboxypropiony oxyethyl)-2-methyl-5-nitroimidazole is introduced aseptically into an ampul bottle. Then the product is sterilized at 100C for one hour. Meanwhile a solution is prepared with the following composition:
Sodium acetate amino acid or
2 amino ethanol 20 g
Distilled water s.q. 100 cc
The solution thus obtained is sterilized by filtration through a 0.22 membrane; 20 cc of this solution is taken and the content of the ampul bottle dissolved. The solution obtained should be used no later than two hours following its preparation.
Example X
Suspension for oral administration: 1-(2-3'-carboxypropionyl oxyethyl)
2-methyl-5-nitroimidazole 1.5 9
Glass sugar 18 g
Sodium nipagin 0.108g Sodium nipasol 0.0129 Sodium saccharin 0.03g Sodium dibasic phosphate 0.1983 g
Sodium monobasic phosphate 0.1017 g
Carboxymethyl cellulose 0.18 9 Manitol 3.87 g
Total 24 g
The mixture obtained is reconstituted with water to a volume of 60 ml at the time of use. This suspension should be used within seven days at most and the remainder discarded.
Example XI
Unguent for topical preparation: 1-(2-3'-carboxypropionyl oxyethyi)- 2-methyl-5-nitroimidazole 0.750 g Cetyl alcohol 10.5 g
Stearilic alcohol 9.3 g
Liquid vaseline 25.5g Glycerine 15 g
Solid vaseline 33.9 g
Nipagin 0.369 Nipasol 0.09 g Span 60 2.3 g
Tween 60 2.3 9
Claims (14)
1. A pharmaceutical composition containing as active ingredient 1 -(2,3'-carboxypropionyl oxyethyl)-2methyl-5-nitroimidazole or a salt thereof with a pharmaceutically acceptable base or acid.
2. A composition as claimed in claim 1 wherein said base is derived from ammonia, alkali or alkaline earth metals.
3. A composition as claimed in claim 1 wherein said acid is an aliphatic amino acid.
4. A composition as claimed in any preceding claim, containing a pharmaceutically acceptable carrier.
5. A composition as claimed in claim 4, in which the carrier is a solid, liquid or unguent pharmaceutical carrier.
6. A composition as claimed in any preceding claim in a form suitable for parenteral administration.
7. A composition as claimed in any of the preceding claims 1 - 5 in a form suitable for oral administration.
8. A composition as claimed in any of the preceding claims 1 - 5 in a form suitable for topical administration.
9. A composition as claimed in any of the preceding claims 1 - 5 in a form suitable for rectal administration.
10. A composition as claimed in any of the preceding claims 1 - 5 in a form suitable for vaginal administration.
11. A composition as claimed in claim 1 in a form suitable for use as a prophylactic agent in surgery.
12. A composition as claimed in any preceding claim in units each containing a unitary dose of the said active ingredient.
13. A method of preparing a pharmaceutical composition comprising admixing with a pharmaceutically acceptable carrier or inert diluent a therapeutically effective amount of 1 -(2-3'-carboxyprnpionyl oxyethyl)-2methyl-5-nitro-imidazole or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition according to any one of Examples I to Xl hereinbefore.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX809191U MX6789E (en) | 1980-12-03 | 1980-12-03 | PROCEDURE FOR THE PREPARATION OF ANTIBACTERIAL COMPOSITIONS BASED ON 1- (2,3'-CARBOXIPROPIONILOXIETIL) -2-METHYL-5-NITROIMIDAZOLE |
Publications (1)
Publication Number | Publication Date |
---|---|
GB2089208A true GB2089208A (en) | 1982-06-23 |
Family
ID=19741552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8136309A Withdrawn GB2089208A (en) | 1980-12-03 | 1981-12-02 | Antibacterial compositions containing 1-(2,3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPS57188518A (en) |
BE (1) | BE891284A (en) |
CA (1) | CA1184120A (en) |
CH (1) | CH652597A5 (en) |
DE (1) | DE3147959A1 (en) |
FR (1) | FR2494993A1 (en) |
GB (1) | GB2089208A (en) |
IT (1) | IT1145989B (en) |
LU (1) | LU83802A1 (en) |
MX (1) | MX6789E (en) |
NL (1) | NL8105449A (en) |
PT (1) | PT74056B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0140395A1 (en) * | 1983-06-21 | 1985-05-08 | Pietro Isnardi & C. Spa | Water soluble derivatives of 1-(2-hydroxyethyl)-2-methyl-5-nitro-imidazole having therapeutical activity, process for its preparation and related pharmaceutical compositions |
EP0490450A1 (en) * | 1990-12-11 | 1992-06-17 | Yamanouchi Europe B.V. | Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB983123A (en) * | 1961-07-07 | 1965-02-10 | Rhone Poulenc Sa | Improvements in or relating to imidazole derivatives |
-
1980
- 1980-12-03 MX MX809191U patent/MX6789E/en unknown
-
1981
- 1981-11-27 PT PT74056A patent/PT74056B/en unknown
- 1981-11-27 IT IT12688/81A patent/IT1145989B/en active
- 1981-11-30 BE BE//206684A patent/BE891284A/en not_active IP Right Cessation
- 1981-12-01 LU LU83802A patent/LU83802A1/en unknown
- 1981-12-01 CH CH7680/81A patent/CH652597A5/en not_active IP Right Cessation
- 1981-12-02 GB GB8136309A patent/GB2089208A/en not_active Withdrawn
- 1981-12-02 FR FR8122594A patent/FR2494993A1/en active Pending
- 1981-12-02 NL NL8105449A patent/NL8105449A/en not_active Application Discontinuation
- 1981-12-03 CA CA000391456A patent/CA1184120A/en not_active Expired
- 1981-12-03 DE DE19813147959 patent/DE3147959A1/en not_active Withdrawn
- 1981-12-03 JP JP56193768A patent/JPS57188518A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0140395A1 (en) * | 1983-06-21 | 1985-05-08 | Pietro Isnardi & C. Spa | Water soluble derivatives of 1-(2-hydroxyethyl)-2-methyl-5-nitro-imidazole having therapeutical activity, process for its preparation and related pharmaceutical compositions |
EP0490450A1 (en) * | 1990-12-11 | 1992-06-17 | Yamanouchi Europe B.V. | Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines |
WO1992010502A1 (en) * | 1990-12-11 | 1992-06-25 | Brocades Pharma B.V. | Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastro-intestinal medicines |
Also Published As
Publication number | Publication date |
---|---|
FR2494993A1 (en) | 1982-06-04 |
PT74056B (en) | 1983-04-26 |
NL8105449A (en) | 1982-07-01 |
BE891284A (en) | 1982-06-01 |
PT74056A (en) | 1981-12-01 |
IT8112688A0 (en) | 1981-11-27 |
JPS57188518A (en) | 1982-11-19 |
IT1145989B (en) | 1986-11-12 |
LU83802A1 (en) | 1983-09-01 |
MX6789E (en) | 1986-07-21 |
CH652597A5 (en) | 1985-11-29 |
DE3147959A1 (en) | 1983-03-24 |
CA1184120A (en) | 1985-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1544173A3 (en) | Method of producing sukralphate | |
US3697652A (en) | N-acetylglucosamine for treating degenerative afflictions of the joints | |
US4450170A (en) | Treatment of diarrhoea with 2-aminoimidazoline derivatives | |
AU8436691A (en) | Pharmaceutical composition of florfenicol | |
US6461646B2 (en) | Pharmaceutical composition for preventing and/or curing digestive disorders | |
ES8401492A1 (en) | Cephalosporin derivatives and process for their preparation. | |
EP0275457B1 (en) | Solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate | |
JPS59144779A (en) | (+)catechine salt | |
WO2012057381A1 (en) | Adhesion barrier containing hyaluronic acids and l-arginine | |
US5633240A (en) | Parenteral solutions containing metolazone | |
US3144387A (en) | Anti-inflammatory compositions | |
US4397845A (en) | Lincomycin 3-(5'-adenylate) as anesthetic | |
GB2089208A (en) | Antibacterial compositions containing 1-(2,3'-carboxypropionyl oxyethyl)-2-methyl-5-nitroimidazole | |
JPS58189114A (en) | Antitumor agent | |
JPS6011026B2 (en) | Production method of new amino acid derivatives | |
JPS595185A (en) | Novel pyrazolopyridine derivative | |
US3299124A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
US3459854A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
GB2083749A (en) | Drug combination comprising ambroxol and an antibiotic for the treatment of infectious diseases of the respiratory tract | |
EP0238207B1 (en) | Bactericidal mixtures | |
US3509256A (en) | Lincomycin-2-phosphate antibiotic compositions and process of treatment | |
US4062974A (en) | Method for treating drepanocytosis | |
US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
US3519712A (en) | Therapeutic compositions comprising n-methylglucamine and coumermycin or salts thereof | |
US3993778A (en) | Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |